en · de · es · fr · pt
sr9009-notes.peptides6088.com › Guide › Background And Mechanism Of Sr9009 — Common Mistakes

Background And Mechanism Of Sr9009 — Common Mistakes

By Editorial Desk · published 2026-01-29 · last reviewed 2026-03-19 · Guide

NR1D1 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2026-03-19. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Mechanism of SR9009

SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.

SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.

Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.

Analytical and Handling Considerations

SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.

For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.

Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall-molecule ligand; not a hormone or peptide
Molecular formulaC20H24ClN3O4SReported for the free base
CAS Registry Number1379686-30-2Unique chemical identifier
Common synonymsSR9009; stenabolicStenabolic is informal and not an official name
Reported targetsREV-ERBα and REV-ERBβNuclear receptors linked to circadian and metabolic regulation

Analytical Detection and Laboratory Handling

In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.

Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.

Related pages on this site

SR9009 Background and Receptor Mechanism

SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.

SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.

Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.

Background and Receptor Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.

At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.

SR9009 Handling and Quality Control

Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.

SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.

Notes from published material

=== Unclaimed property === After being elected treasurer, Kennedy drafted a bill to move the work of managing unclaimed property from the Department of Revenue to the state treasurer's office to allow him to continue the work he had started as secretary of revenue under Governor Foster. Kennedy led regular events to raise awareness about unclaimed property at malls and other public spaces, returning $400 million to 600,000 Louisianians. He told reporters that the state had returned money to many prominent Louisianians, including Foster, Archie Manning, and John Goodman. Under Kennedy's leadership, the treasury uncovered $45 million in unclaimed death benefits alone. With the money that remained unclaimed, Kennedy convinced the state legislature to establish a $200 million fund to repay construction bonds that were used to build I-49. He worked with Moody's and Standard & Poor's to maintain the state's favorable bond rating throughout the project.

Literary reflections of Cossack culture abound in Russian, Ukrainian, and Polish literature, particularly in the works of Nikolai Gogol (Taras Bulba), Taras Shevchenko, Mikhail Sholokhov (And Quiet Flows the Don), Henryk Sienkiewicz (With Fire and Sword). One of Leo Tolstoy's first novellas, The Cossacks, depicts their autonomy and estrangement from Moscow and from centralized rule. Many of Isaac Babel's stories (for instance, those in Red Cavalry) depict Cossack soldiers, and were based on Babel's experiences as a war correspondent attached to the 1st Cavalry Army. Polish Romantic literature also commonly dealt with Cossack themes. Some of the Polish writers of this period (for instance, Michał Czajkowski and Józef Bohdan Zaleski) were known as "Cossacophiles" who wholeheartedly celebrated the Cossack history and lifestyle in their works. Others, such as Henryk Rzewuski and Michał Grabowski, were more critical in their approach. In the literature of Western Europe, Cossacks appear in Byron's poem "Mazeppa", Tennyson's "The Charge of the Light Brigade", and Richard Connell's short story "The Most Dangerous Game". In many stories by adventure writer Harold Lamb, the main character is a Cossack. During the Imperial period, Cossacks acquired an image as the ferocious defenders of the antisemitic Russian state.

== Research development == In 1978 he began research at McGill on a dietary protein source that would boost immune system performance. Bounous contends that a deficiency in the protein glutathione is linked to several diseases, and that a lack of innate cysteine that inhibits glutathione production. Cysteine-Rich Protein Reverses Weight Loss in Lung Cancer Patients Receiving Chemotherapy or Radiotherapy Molecular pathogenesis and prevention of prostate cancer. Whey protein concentrate (WPC) and glutathione modulation in cancer treatment. The use of a whey protein concentrate in the treatment of patients with metastatic carcinoma: a phase I-II clinical study. Competition for glutathione precursors between the immune system and the skeletal muscle: pathogenesis of chronic fatigue syndrome.

Counterfeit drugs are a serious problem. People can potentially ingest useless or dangerous drugs without their knowledge. Custom package seals, authentication labels, holograms, and security printing can be valued parts of an entire security system. They help verify that enclosed drugs are what the package says they are. Drug counterfeiters, however, often work with package counterfeiters, some of whom can be sophisticated. No packaging system is completely secure.

Sources: en.wikipedia.org

Further detail

== Sports == F2 Logistics is also involved in sports. It formerly owned the F2 Logistics Cargo Movers, a women's volleyball team active from 2016 to 2023. It competed in the Philippine Super Liga and Premier Volleyball League. It also sponsors the La Salle women's volleyball team and the Parañaque Patriots basketball team of the Maharlika Pilipinas Basketball League.

Recent college reforms envisage offering more flexible degrees, creating online learning tools, and inviting foreign universities to set up campuses in India. However, large gaps remain between rural and urban areas. School quality, campus building conditions, and computer access vary substantially based on a student's gender and family's wealth. Poor job prospects for graduates and uneven rule enforcement across different states have faced criticism from researchers and the public alike.

== Honors and awards == Independent Scientist Research (K02) Award, National Institute of Mental Health, 2002–2007. Fellow, Association for Psychological Science, 2003. Fellow, Society for Personality and Social Psychology, 2005. Fellow, American Psychological Association, 2005. Career Trajectory Award, Society of Experimental Social Psychology, 2006. Cattell Fund Fellowship, 2007–2008. NIH Director's Pioneer Award, 2007–2012, to study how the brain creates emotion. Kavli Fellow, National Academy of Sciences, 2008. Elected Fellow, American Association for the Advancement of Science, 2008. Arts in Academics award, University of Waterloo, 2010. Excellence in Research and Creative Activity Award, Northeastern University, 2012. Elected Fellow, Royal Society of Canada, 2012. Award for Distinguished Service in Psychological Science, American Psychological Association, 2013. Elected Fellow, Society of Experimental Psychologists, 2013. Diener Award in Social Psychology, Society for Personality and Social Psychology, 2014. Heritage Wall of Fame, Foundation for Personality and Social Psychology, 2016. Mentor Award for Lifetime Achievement, Association for Psychological Science, 2018. Elected Fellow, American Academy of Arts and Sciences, 2018. President, Association for Psychological Science, 2019–2020. Guggenheim Fellowship in neuroscience, 2019. John P. McGovern Award in the Behavioral Sciences, American Association for the Advancement of Science, 2020. APA Award for Distinguished Scientific Contributions, American Psychological Association, 2021.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.

Is SR9009 approved for human use?

No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.

How does SR9009 differ from natural REV-ERB ligands?

Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.

How is SR9009 detected in laboratory samples?

Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.

Network